Investor Presentaiton

31st January 2024 Our Business is well diversified & gives us an edge India Branded Generics Asia Other Business Africa Institutional Africa 4 8 8 Anti Malaria T Segments T Segments T Segments T Segment US Generics 54 Approved ANDAS (includes 2 Tentative) ~50% First to market Leadership In Sub therapeutic segments Leading Brands in segments 1st Generic prequalified by WHO 22 Under Approval ANDAS 300+ Products 200+ Products 200+ Products Note: All data as of Mar-23 unless otherwise specified 1Bn+ Patients Treated 44 Products on shelf 8 ajanta

View entire presentation